{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-098485","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.256709+00:00","generated_at":"2026-05-31T08:41:32.074908+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Adicet Bio appoints Dr. Lloyd Klickstein to its Board, effective August 19, 2024","bullets":["Dr. Michael Kauffman resigned from Board and Nominating Committee effective Aug 19, 2024; no disagreement cited.","Dr. Lloyd Klickstein, M.D., Ph.D., appointed as Class III director and to Nominating Committee; term through 2027 annual meeting.","Klickstein received an option for 70,200 shares, vesting over 36 months, plus standard non-employee director compensation.","Klickstein previously served as Adicet's Chief Innovation Officer and has leadership experience at Novartis and Eli Lilly."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-098485","json":"https://secwatch.observer/filing/0000950170-24-098485.json","markdown":"https://secwatch.observer/filing/0000950170-24-098485.md","text":"https://secwatch.observer/filing/0000950170-24-098485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/acet-20240815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:41:32.074908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62173e1aa4","claim":"Michael Kauffman resigned as Director at Adicet Bio, Inc..","evidence_excerpt":"Michael Kauffman, M.D., Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Nominating and Corporate Governance Committee (the “NCG Committee”), effective as of August 19, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9c54fc336d","claim":"Lloyd Klickstein was appointed as Director at Adicet Bio, Inc..","evidence_excerpt":"the Board appointed Lloyd Klickstein, M.D., Ph.D. to the Board, effective as of August 19, 2024, to fill the vacancy on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}